Thousands of patients across the United States are being urged to check their prescription medicines after a major nationwide recall involving blood pressure tablets.
Macleods Pharma USA has voluntarily recalled 3,744 bottles of blood pressure medication after the products failed federal quality tests.
The US Food and Drug Administration (FDA) classified the recall as Class II on October 26, 2026. The company had initiated the recall on October.
Which Blood Pressure Medicines Are Being Recalled?
The recall affects a combination medication containing olmesartan medoxomil, amlodipine and hydrochlorothiazide.
The affected tablets contain 40mg, 10mg and 12.5mg of the respective ingredients.
According to the FDA, the recalled products include:
-
3,528 bottles containing 30 tablets: Lot 12251163A, NDC 33342-246-07.
-
216 bottles containing 90 tablets: Lot 12251163B, NDC 33342-246-10.
Both batches expire on May 31, 2027.
Why Did the FDA Recall These Tablets?
The FDA identified failed dissolution specifications as the reason for the recall.
This means the tablets did not dissolve as required during testing.
Improper dissolution may affect how the medication releases its active ingredients, potentially reducing treatment effectiveness.
What Does the Class II Recall Mean?
A Class II recall indicates that using the affected medicine may cause temporary or medically reversible health problems.
However, the FDA considers the likelihood of serious consequences remote.
What Should Patients Do Now?
Patients should immediately check their medicine packaging for the affected batch numbers.
Anyone possessing the recalled tablets should contact their pharmacist or healthcare provider for guidance.
Patients should not stop taking prescribed blood pressure medication without medical advice, because uncontrolled hypertension can create serious health risks.
The nationwide recall remains ongoing.
